AIMS: Pre-treatment with mineralocorticoid receptor (MR) antagonists is reported to reduce myocardial infarct size from ischaemia/reperfusion. Here, we tested whether the MR antagonists potassium canrenoate and eplerenone could protect in the more clinically relevant schedule of administration at the end of ischaemia. METHODS AND RESULTS: In all models, hearts were subjected to 30 min regional ischaemia followed by 120 min (rabbits 4 h) reperfusion. A bolus of canrenoate 5 min prior to reperfusion in open-chest mice decreased infarct size in a dose-dependent manner. Maximum protection was seen at 1 mg/kg where infarction was 18% of that in the control (P < 0.001). Ecto-5'-nucleotidase (CD73) as well as adenosine A(2b) receptor knock-out mice could no longer be protected, suggesting a role for adenosine and the A(2b) receptor in the mechanism. A 1 mg/kg bolus of canrenoate prior reperfusion also reduced infarct size in open-chest rabbits. To explore the underlying mechanisms, we studied isolated rat hearts. Eplerenone (10 microM) at the end of ischaemia was similarly protective in the rat heart and the protection was abolished by co-treatment with inhibitors of the adenosine receptor, protein kinase C, PI3-kinase, and ERK. In addition, eplerenone or canrenoate treatment increased phosphorylation of the pro-survival kinases Akt and ERK1/2 at reperfusion in the rat hearts. CONCLUSION: Taken together, MR antagonists when given at the end of ischaemia are highly effective and potent cardioprotective drugs with a signalling similar to that of ischaemic pre-conditioning and, hence, could be a very promising candidate for the treatment of acute myocardial infarction in man.
AIMS: Pre-treatment with mineralocorticoid receptor (MR) antagonists is reported to reduce myocardial infarct size from ischaemia/reperfusion. Here, we tested whether the MR antagonists potassium canrenoate and eplerenone could protect in the more clinically relevant schedule of administration at the end of ischaemia. METHODS AND RESULTS: In all models, hearts were subjected to 30 min regional ischaemia followed by 120 min (rabbits 4 h) reperfusion. A bolus of canrenoate 5 min prior to reperfusion in open-chest mice decreased infarct size in a dose-dependent manner. Maximum protection was seen at 1 mg/kg where infarction was 18% of that in the control (P < 0.001). Ecto-5'-nucleotidase (CD73) as well as adenosine A(2b) receptor knock-out mice could no longer be protected, suggesting a role for adenosine and the A(2b) receptor in the mechanism. A 1 mg/kg bolus of canrenoate prior reperfusion also reduced infarct size in open-chest rabbits. To explore the underlying mechanisms, we studied isolated rat hearts. Eplerenone (10 microM) at the end of ischaemia was similarly protective in the rat heart and the protection was abolished by co-treatment with inhibitors of the adenosine receptor, protein kinase C, PI3-kinase, and ERK. In addition, eplerenone or canrenoate treatment increased phosphorylation of the pro-survival kinases Akt and ERK1/2 at reperfusion in the rat hearts. CONCLUSION: Taken together, MR antagonists when given at the end of ischaemia are highly effective and potent cardioprotective drugs with a signalling similar to that of ischaemic pre-conditioning and, hence, could be a very promising candidate for the treatment of acute myocardial infarction in man.
Authors: J S Silvestre; C Heymes; A Oubénaïssa; V Robert; B Aupetit-Faisant; A Carayon; B Swynghedauw; C Delcayre Journal: Circulation Date: 1999-05-25 Impact factor: 29.690
Authors: Xi-Ming Yang; J Bradley Proctor; Lin Cui; Thomas Krieg; James M Downey; Michael V Cohen Journal: J Am Coll Cardiol Date: 2004-09-01 Impact factor: 24.094
Authors: Hajime Kin; Zhi-Qing Zhao; He-Ying Sun; Ning-Ping Wang; Joel S Corvera; Michael E Halkos; Faraz Kerendi; Robert A Guyton; Jakob Vinten-Johansen Journal: Cardiovasc Res Date: 2004-04-01 Impact factor: 10.787
Authors: Carmen Methner; Katharina Schmidt; Michael V Cohen; James M Downey; Thomas Krieg Journal: Am J Physiol Heart Circ Physiol Date: 2010-08-13 Impact factor: 4.733
Authors: Heerajnarain Bulluck; Georg M Fröhlich; Shah Mohdnazri; Reto A Gamma; John R Davies; Gerald J Clesham; Jeremy W Sayer; Rajesh K Aggarwal; Kare H Tang; Paul A Kelly; Rohan Jagathesan; Alamgir Kabir; Nicholas M Robinson; Alex Sirker; Anthony Mathur; Daniel J Blackman; Cono Ariti; Arvindra Krishnamurthy; Steven K White; Pascal Meier; James C Moon; John P Greenwood; Derek J Hausenloy Journal: Clin Cardiol Date: 2015-05 Impact factor: 2.882
Authors: Carmen Methner; Guido Buonincontri; Chou-Hui Hu; Ana Vujic; Axel Kretschmer; Stephen Sawiak; Adrian Carpenter; Johannes-Peter Stasch; Thomas Krieg Journal: PLoS One Date: 2013-12-31 Impact factor: 3.240
Authors: Edward T Chouchani; Victoria R Pell; Edoardo Gaude; Dunja Aksentijević; Stephanie Y Sundier; Ellen L Robb; Angela Logan; Sergiy M Nadtochiy; Emily N J Ord; Anthony C Smith; Filmon Eyassu; Rachel Shirley; Chou-Hui Hu; Anna J Dare; Andrew M James; Sebastian Rogatti; Richard C Hartley; Simon Eaton; Ana S H Costa; Paul S Brookes; Sean M Davidson; Michael R Duchen; Kourosh Saeb-Parsy; Michael J Shattock; Alan J Robinson; Lorraine M Work; Christian Frezza; Thomas Krieg; Michael P Murphy Journal: Nature Date: 2014-11-05 Impact factor: 49.962
Authors: T N A van den Berg; Jaap Deinum; Albert Bilos; A Rogier T Donders; Gerard A Rongen; Niels P Riksen Journal: PLoS One Date: 2014-10-30 Impact factor: 3.240
Authors: Edward T Chouchani; Carmen Methner; Sergiy M Nadtochiy; Angela Logan; Victoria R Pell; Shujing Ding; Andrew M James; Helena M Cochemé; Johannes Reinhold; Kathryn S Lilley; Linda Partridge; Ian M Fearnley; Alan J Robinson; Richard C Hartley; Robin A J Smith; Thomas Krieg; Paul S Brookes; Michael P Murphy Journal: Nat Med Date: 2013-05-26 Impact factor: 53.440